瑞宁得已被批准作为绝�t�后晚期乳腺癌妇女的首选内分泌治疗。不论是晚期乳腺癌的一线治疗还是二线治疗，瑞宁得是惟一有一致性疗效和耐受性数据的芳香化酶抑制剂。

• 瑞宁���的疗效和耐受性显著优于三苯氧胺[1,2].
• 瑞宁得是惟一有成熟生存率受益优势超过醋酸甲地孕酮的芳香化酶抑制剂[3].
• 瑞宁得是选择性最强的芳香化酶抑制剂.*
  
  *已经评价了三代芳香化酶抑制剂的选择性。有数据表明，并非所有这类药物都有与瑞宁得相同的良好药理特点。
  
  
• 一线治疗
• 二线治疗

参考文献

1. Bonneterre J, Buzdar AU, Nabholtz JM, et al. Anastrozole is superior tovtamoxifen as first-line therapy in horme-receptor-positive advanced breast warcinoma. Results of tworandomizedtrialsb designedforqombinednalysis. Cancer 001; 92:w 2247-2258.
2. Milla-Santos A, Milla L, Portella J, et al. Anastrozolesvsc amoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A double-blind, prospective randomized Phase IIIastudy. EuruJ Cancer 2002;q 8 (Supplg 3): S67, Abstr 112.
3. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based upon a combined analysis of data from two mature Phase IIIdrials. Cancer 1998; 83: 1142-1152. Erratum: ibid 1999;g5: 1010.

q瑞宁得治疗晚期乳腺癌 En UN Number v l Women r瑞宁得治疗晚期乳腺癌 En UN Number p s h h Hot Hot